Dr. Tara L. Lin, MD

Dr. Lin practices at The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System.

Dr. Lin's NPI, 1013172253, was assigned on July 28, 2008. Dr. Lin holds Kansas license 04-35300.

Dr. Lin's primary practice is The University of Kansas Hospital, at 4000 Cambridge Street, Kansas City, KS 66160 in Wyandotte County. The practice phone is (913) 588-5000.

Dr. Lin's primary practice is The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System. The medical group on file is KU Dental Associates.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Lin's licenses on file in 2 states: Kansas and Louisiana.

CMS data shows 674 Medicare services from Dr. Lin across 8 procedure codes in 2024, for 80 Medicare patients. Medicare paid $48,655 for them.

CMS counts 80 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have high blood pressure, and 73% have high cholesterol. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 72, with 55% women.

In 2024, Dr. Lin wrote 132 Medicare Part D claims for 32 patients. 72% of them were for generic drugs. CMS names the drug for 32 of them, across 2 drugs with 11 or more claims each, at $30,212 in total drug cost. In 2023, CMS named 23 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Lin for performance year 2024, reported through an alternative payment model (APM). Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 78 papers to Dr. Lin, published from 2010 to 2025. 2018 was the busiest year, with 7. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Cytarabine. Dr. Lin has published most often in Leuk Lymphoma. Dr. Lin's most frequent co-authors are Sunil H. Abhyankar, MD, Omar Salah Aljitawi, MD and Siddhartha Ganguly, MD.

Dmand AI links Dr. Lin to 10 clinical trials, 4 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Leukemia, Myeloid. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 53 general payments to Dr. Lin from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Syndax Pharmaceuticals, Inc. paid the most, $9,883. It also lists 12 research payments totaling $2,113 from 2016 to 2025.